S. Aamdal

Publication List Details

Period

1992 - 2005

Number

16

Co-Authors

Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma (2005)

Millward, MJ, Joshua, A, Kefford, R, Aamdal, S, Thomson, D, Hersey, P, ...

Purpose: To determine the activity and tolerability of SAM496A, an inhibitor of S-adenosylmethionine decarboxylase (SAMDC), in patients with metastatic melanoma who had not received prior...

Phase II study of E7070 in patients with metastatic melanoma (2005)

Smyth, J. F., Aamdal, S., Awada, A., Dittrich, C., Caponigro, F., Schöffski, P., ...

E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m2 of E7070 as a...

Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG) (2000)

Aamdal, S, Awada, A, Calvert, H, Fumoleau, P, Sorio, R, ...

PURPOSE: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. PATIENTS AND METHODS: Carzelesin was used as second- or third-line chemotherapy in...

Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trials Group (1994)

Sessa, C., Aamdal, S., Wolff, I., Eppelbaum, R., Smyth, J. F., Sulkes, A., ...

Background: Gemcitabine is a water-soluble analogue of deoxycytidine which has shown significant antitumour activity in a broal panel of slow-growing murine and human carcinomas. Objective responses...

Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods.

Beiske, K., Myklebust, A. T., Aamdal, S., Langholm, R., Jakobsen, E., Fodstad, O.

An immunocytochemical method, involving four monoclonal antibodies (MAbs) previously selected for their specific binding to small cell lung cancer (SCLC) cells in human bone marrow, was used for...

Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients.

Tefre, T., Børresen, A. L., Aamdal, S., Brøgger, A.

We studied 83 lung cancer patients and 129 controls for the EcoRI polymorphism of the L-myc gene. No association was found between the L-myc RFLP and increased risk of metastasis, either to lymph...

Characteristics of human tumour xenografts transplanted under the renal capsule of immunocompetent mice.

Aamdal, S., Fodstad, O., Nesland, J. M., Pihl, A.

Human tumour lines established in athymic nude mice were grafted under the renal capsule of immunocompetent mice. Grafts from 27 human tumour lines comprising 9 malignant melanomas, 10 sarcomas, 2...

Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease.

Gundersen, S., Aamdal, S., Fodstad, O.

A phase II trial with mitozolomide was carried out in patients with malignant melanoma, since in preclinical studies this new imidazotetrazine had shown promising effects against human melanoma...

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

Hanauske, A. R., Catimel, G., Aamdal, S., Paridaens, R., Pavlidis, N., ...

Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca...

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.

McLeod, H. L., Murray, L. S., Wanders, J., Setanoians, A., Graham, M. A., Pavlidis, N., ...

Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines...

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

Mu, L J, Kyte, J A, Kvalheim, G, Aamdal, S, Dueland, S, Hauser, M, ...

Here, we present results from a clinical trial employing a new vaccination method using dendritic cells (DCs) transfected with mRNA from allogeneic prostate cancer cell lines (DU145, LNCaP and PC-3)....

Selection of anti-SCLC antibodies for diagnosis of bone marrow metastasis.

Myklebust, A. T., Beiske, K., Pharo, A., Davies, C. D., Aamdal, S., Fodstad, O.

The binding profile of 17 monoclonal antibodies (MAbs) to small lung cancer cell lines and normal bone marrow and peripheral blood cells was studied by immunocytochemistry and flow cytometry. At...